Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
A â??cocktailâ? approach involving the simultaneous administration of multiple cytochrome P450 (CYP)-specific probes concurrently
detects the activity of multiple CYP enzymes. We developed and validated a rapid and selective liquid chromatography tandem
mass spectrometry (LC-MS/MS) method to determine the plasma concentrations of 5 CYP probe drugs and metabolites (caffeine/
paraxanthine, CYP1A2 substrate; losartan/losartan carboxylic acid (E3174), CYP2C9 substrate, omeprazole/5-hydroxy omeprazole,
CYP2C19 substrate; dextromethorphan/dextrorphan, CYP2D6 substrate; and midazolam/1â??-hydroxymidazolam, CYP3A4 substrate)
by a single-step extraction followed by a single LC-MS/MS run. The assay had high accuracy and reliability for plasma samples. Next,
we clarified the chronological changes in rifampicin-induced CYP enzyme activity after rifampicin discontinuation because the time
course after drug treatment discontinuation has received little attention. Thirteen volunteers were administered rifampicin (450 mg)
once daily, and the cocktail method was repeatedly performed. A 7-day rifampicin administration increased CYP2C19 and CYP3A
enzyme activities. The induced CYP2C19 and CYP3A activities remained elevated at 4 days after rifampicin discontinuation and
returned to baseline levels 8 days after rifampicin discontinuation. However, CYP1A2 and CYP2D6 enzyme activities showed no
significant changes and CYP2C9 enzyme activity increased with rifampicin with a tendency toward statistical significance. These
results suggest that drug interactions can occur even after rifampicin discontinuation. In conclusion, the advantage of our cocktail
approach is that it enables in vivo assessment of the activity of various drug-metabolizing enzymes and the detection of potential drug
interactions in a single assay.
Biography
Shinya Uchida received his PhD degree from the University of Shizuoka in 1999. He served as a Clinical Pharmacist at the University Hospital of Hamamatsu School of Medicine. At present, he is an Associate Professor at the University of Shizuoka and his major interests include clinical pharmaceutical science, clinical pharmacology and pharmacokinetics. He has published 69 papers in peer-reviewed journals.